Results 251 to 260 of about 268,538 (298)

Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

, 1995
Objective. —To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on mortality and morbidity in patients with symptomatic congestive heart failure. Data Sources and Study Selection.
R. Garg, S. Yusuf
semanticscholar   +1 more source

angiotensin converting enzyme inhibitors

2012
More than 30 years since their discovery, angiotensin-converting enzyme (ACE) inhibitors still represent one of the most commonly prescribed medications for treating hypertension and one of the favored first-line agents, particularly in the presence of high-risk conditions, such as diabetes.
GENTILE, GIORGIO, REBOLDI, Gianpaolo, ANGELI, FABIO, G. Mazzotta, P. Verdecchia   +4 more
openaire   +4 more sources

Angiotensin converting enzyme inhibitors

Pharmaceutisch Weekblad Scientific Edition, 1982
Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described.
openaire   +2 more sources

A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery

Anesthesia and Analgesia, 2018
BACKGROUND: The global rate of major noncardiac surgical procedures is increasing annually, and of those patients presenting for surgery, increasing numbers are taking either an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin receptor ...
C. Hollmann, N. L. Fernandes, B. Biccard
semanticscholar   +1 more source

Angiotensin-converting enzyme inhibitors

2001
Publisher Summary Angiotensin-converting enzyme (ACE) inhibitors were first studied clinically in the 1970s. ACE inhibitors were discovered by taking advantage of previous basic research on the physiology of sodium, potassium, and water homeostasis and blood pressure regulation, in a reciprocal way ACE have also advanced research in this field, and ...
Arthur A. Patchett, Joël Ménard
openaire   +3 more sources

Angiotensin-Converting Enzyme Inhibitors

AACN Advanced Critical Care, 1992
The angiotensin-converting enzyme (ACE) inhibitors available today include Captopril (Capoten), enalapril (Vasotec), enaloprilat (Vasotec IV), lisinopril (Prinivil, Zestril), benazepril (Lotensin), fosinopril (Monopril), and ramipril (Atace). These drugs are used in the treatment of hypertension and congestive heart failure.
openaire   +3 more sources

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1987
In summary, ACE inhibitors are effective in reducing blood pressure as initial therapy in some hypertensive patients and in combination with diuretics and other agents in virtually all hypertensives. ACE inhibitors are uniquely advantageous because of their favorable hemodynamic effects, the lack of adverse metabolic effects, and their ability to ...
openaire   +3 more sources

Angiotensin-Converting Enzyme Inhibitors and Glycosuria

Archives of Internal Medicine, 1992
Renal glycosuria associated with the use of angiotensin-converting enzyme inhibitors has been previously reported in two patients. A third patient was studied who developed isolated glycosuria associated with lisinopril therapy. As in the two previously described patients, this patient had a normal serum glucose level, underlying hypertension, and ...
Mordecai M. Popovtzer, James J. Milavetz
openaire   +3 more sources

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.

New England Journal of Medicine, 1993
Background. Although digoxin is effective in the treatment of patients with chronic heart failure who are receiving diuretic agents, it is not clear whether the drug has a role when patients are receiving angiotensin-converting-enzyme inhibitors, as is ...
M. Packer, M. Gheorghiade, J. B. Young, P. Costantini, K. Adams, R. Cody, L. K. Smith, Lucy Van Voorhees, L. Gourley, M. K. Jolly   +9 more
semanticscholar   +1 more source

The Future of Angiotensin-Converting Enzyme Inhibitors

Journal of Cardiovascular Pharmacology, 1985
After a brief introduction summarizing their historical development and the classification of angiotensin-converting enzyme inhibitors by chemical structure, the considerations involved in developing new and improved drugs of this pharmacologic class are discussed.
openaire   +3 more sources